At Arbele, we are revolutionizing gastrointestinal cancers and solid tumors treatment through our groundbreaking Cadherin-17 biomarker technology. Our proprietary CDH17 biomarker …

Arbele is dedicated to revolutionizing the treatment of gastrointestinal cancers through the development of cutting-edge immunotherapy platforms. Our mission is to provide hope and …

Explore our innovative development pipeline for gastrointestinal cancers. Arbele's product pipeline including clinical-stage biotech immunotherapy, precision medicine, biotechnology research, …

Arbele正研发的ARB202 是一种CDH17xCD3 T细胞接合双抗体，可诱发T细胞介导的细胞杀伤和癌症免疫。 Arbele正在澳洲进行ARB202的首次人体临床试验，预计在2022年4月招募第一位进 …

艾贝乐的愿景是用突破性的创新免疫疗法早筛和治愈胃肠道（GI）癌症。 我们努力提供全新及独特的胃肠道癌症药物和优质的体外诊断方法，用于早期疾病干预。 我们拥有覆盖全球的CDH17 …

Arbele is a biopharmaceutical company which has established R&D sites in the Seattle area and at the Hong Kong Science and Technology Park. To more effectively treat solid tumors, Arbele …

2024年4月26日 · ARB202 is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells. The unique …

CDH17 ADC(Arbele): 一种CDH17拮抗剂、微管蛋白抑制剂药物，由Arbele Corp. (Arbele Corp.)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: CDH17拮抗剂(Cadherin-17 …

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented …

2024年10月10日 · Arbele has entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of …